Geneva, Dec. 23 -- International Clinical Trials Registry received information related to the study (ACTRN12625001397404) titled 'Effect of medications on bladder pain during Bacillus Calmette-Guerin (BCG) treatment for bladder cancer patients with bladder cancer: a pilot randomised clinical trial' on Dec. 12.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Assignment: Parallel
Type of endpoint: Efficacy
Primary Sponsor: SALHN
Condition:
Non-muscle invasive bladder cancer
Non-muscle invasive bladder cancer
Cancer - Bladder
Intervention:
Arm 1: Mirabegron
Type administered: Oral tablet.
Dose and schedule: Mirabegron 50 mg taken once daily.
Duration ...